<table border="single" id="id_abfd39b1-1826-4523-90c6-34fca5b04118" width="497.000" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="33.8%"></col>
<col width="34.4%"></col>
<col width="31.8%"></col>
<tbody>
<tr id="id_37f8acb6-4b8b-40dd-a68c-d9f094a74ed9">
<td align="center" stylecode="Botrule Toprule Rrule Lrule" valign="top">
<content stylecode="bold">Drug/Drug Class (Mechanism of Interaction by Voriconazole)</content>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Drug Plasma Exposure (C<sub>max</sub> and AUC</content>
<sub>τ )</sub>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Recommendations for Drug Dosage Adjustment/Comments</content>
</td>
</tr>
<tr id="id_95e6ea38-6f0e-4eb7-a638-c908141e4b86">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>Sirolimus* </paragraph>(CYP3A4 Inhibition) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Significantly Increased</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Contraindicated</content>
</td>
</tr>
<tr id="id_9ba0def6-7bd4-456c-8b7a-61cfaa2955d9">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>Rifabutin* </paragraph>(CYP3A4 Inhibition) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Significantly Increased</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Contraindicated</content>
</td>
</tr>
<tr id="id_ba8957ac-120c-4759-8fa2-9e01012afec9">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>Efavirenz**</paragraph>(CYP3A4 Inhibition) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Significantly Increased</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<paragraph>When voriconazole is coadministered with efavirenz, voriconazole</paragraph>maintenance dose should be increased to 400 mg q12h and efavirenz should be decreased to 300 mg q24h </td>
</tr>
<tr id="id_8a5dd2e2-edff-4792-8281-bffe38670c51">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>High dose Ritonavir (400 mg q12h)** (CYP3A4 Inhibition) </paragraph>Low dose Ritonavir (100 mg q12h)** </td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<paragraph>No Significant Effect of Voriconazole on Ritonavir C<sub>max</sub> or AUC<sub>τ</sub>
</paragraph>Slight Decrease in Ritonavir C<sub>max</sub> and AUC<sub>τ</sub>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Contraindicated</content> because of significant reduction of voriconazole C<sub>max</sub> and AUC<sub>τ</sub>
</paragraph>Coadministration of voriconazole and low dose ritonavir (100 mg q12h) should be avoided (due to the reduction in voriconazole C<sub>max</sub> and AUC<sub>τ</sub>) unless an assessment of the benefit/risk to the patient justifies the use of voriconazole </td>
</tr>
<tr id="id_ce49bd5c-2b9a-476b-9211-0cba05b85337">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>Terfenadine, Astemizole, Cisapride, Pimozide, Quinidine </paragraph>(CYP3A4 Inhibition) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Not Studied <content stylecode="italics">In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Drug Plasma Exposure Likely to be Increased </td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Contraindicated</content> because of potential for QT prolongation and rare occurrence of torsade de pointes </td>
</tr>
<tr id="id_3d75f41e-d549-4f67-8ab8-9a89728e9879">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>Ergot Alkaloids </paragraph>(CYP450 Inhibition) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Not Studied<content stylecode="italics"> In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Drug Plasma Exposure Likely to be Increased </td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Contraindicated </content>
</td>
</tr>
<tr id="id_c7725ffe-2e19-49fd-a19e-702a2819c6a2">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>Cyclosporine* </paragraph>(CYP3A4 Inhibition) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">AUC<sub>τ</sub> Significantly Increased; No Significant Effect on C<sub>max</sub>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">When initiating therapy with voriconazole in patients already receiving cyclosporine, reduce the cyclosporine dose to one-half of the starting dose and follow with frequent monitoring of cyclosporine blood levels. Increased cyclosporine levels have been associated with nephrotoxicity. When voriconazole is discontinued, cyclosporine concentrations must be frequently monitored and the dose increased as necessary</td>
</tr>
<tr id="id_3f3e9709-90e0-4ac9-b028-2eccf2fce596">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Methadone*** (CYP3A4 Inhibition) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Increased </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Increased plasma concentrations of methadone have been associated with toxicity including QT prolongation. Frequent monitoring for adverse events and toxicity related to methadone is recommended during coadministration. Dose reduction of methadone may be needed </td>
</tr>
<tr id="id_52d9106e-4387-47f1-9f38-05babe3999a3">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Fentanyl (CYP3A4 Inhibition) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Increased </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Reduction in the dose of fentanyl and other long acting opiates metabolized by CYP3A4 should be considered when coadministered with voriconazole. Extended and frequent monitoring for opiate associated adverse events may be necessary [<content stylecode="italics">see Drug Interactions (<linkhtml href="#i4i_pharmacokinetics_id_af7a42d0-3acb-4743-877b-c335a86419dd">7</linkhtml>)</content>]</td>
</tr>
<tr id="id_85d560a6-dfcd-441f-a8c4-89b0b3eae63e">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Alfentanil (CYP3A4 Inhibition) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Significantly Increased </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Reduction in the dose of alfentanil and other opiates metabolized by CYP3A4 (e.g., sufentanil) should be considered when coadministered with voriconazole. A longer period for monitoring respiratory and other opiate associated adverse events may be necessary [<content stylecode="italics">see Drug Interactions (<linkhtml href="#i4i_pharmacokinetics_id_af7a42d0-3acb-4743-877b-c335a86419dd">7</linkhtml>)</content>]</td>
</tr>
<tr id="id_25e226ab-5943-4d7d-bb19-df2c6150f118">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Oxycodone (CYP3A4 Inhibition) </td>
<td align="center" stylecode="Rrule" valign="top">Significantly Increased </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Reduction in the dose of oxycodone and other long-acting opiates metabolized by CYP3A4 should be considered when coadministered with voriconazole. Extended and frequent monitoring for opiate associated adverse events may be necessary [<content stylecode="italics">see Drug Interactions (<linkhtml href="#i4i_pharmacokinetics_id_af7a42d0-3acb-4743-877b-c335a86419dd">7</linkhtml>)</content>]</td>
</tr>
</tbody>
</table>